by VICO Therapeutics | Apr 3, 2023 | Press Release
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
by VICO Therapeutics | Oct 3, 2022 | Management, Press Release
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
by VICO Therapeutics | Aug 4, 2022 | Management, Press Release
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
by VICO Therapeutics | Jul 29, 2021 | Press Release
Leiden, The Netherlands, 29 July 2021 – VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
by VICO Therapeutics | Jun 29, 2021 | Press Release
Leiden, The Netherlands, 29 June 2021 – VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products...
by VICO Therapeutics | Feb 10, 2021 | Press Release
Leiden, The Netherlands, 10 February 2021 – VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
